# A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

> **NCT01560286** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **BIOLOGICAL:** BMN 165 (rAvPAL-PEG)

## Key facts

- **NCT ID:** NCT01560286
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-09
- **Final completion:** 2015-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01560286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01560286, "A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01560286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*